Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...
May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner ...
OptiTROP-Lung05 randomized 413 untreated, PD-L1 ≥1% advanced NSCLC patients without EGFR/ALK alterations to sac-TMT+pembrolizumab versus pembrolizumab; primary endpoint was PFS. Median PFS was not ...
The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results